## Alexander Buchner

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1387118/publications.pdf

Version: 2024-02-01

169 papers 4,683 citations

94269 37 h-index 58 g-index

181 all docs

181 docs citations

times ranked

181

6441 citing authors

#	Article	IF	Citations
1	A Novel Gene Signature-Based Model Predicts Biochemical Recurrence-Free Survival in Prostate Cancer Patients after Radical Prostatectomy. Cancers, 2020, 12, 1.	1.7	300
2	A New Concept for Early Recovery after Surgery for Patients Undergoing Radical Cystectomy for Bladder Cancer: Results of a Prospective Randomized Study. Journal of Urology, 2014, 191, 335-340.	0.2	171
3	Expression of Indoleamine 2,3-Dioxygenase in Tumor Endothelial Cells Correlates with Long-term Survival of Patients with Renal Cell Carcinoma. Clinical Cancer Research, 2007, 13, 6993-7002.	3.2	149
4	Prospective Evaluation of the Functional Sling Suspension for Male Postprostatectomy Stress Urinary Incontinence: Results after 1 Year. European Urology, 2009, 56, 928-933.	0.9	123
5	Transcript signature predicts tissue NK cell content and defines renal cell carcinoma subgroups independent of TNM staging. Journal of Molecular Medicine, 2012, 90, 55-66.	1.7	114
6	Association Between the Number of Dissected Lymph Nodes During Pelvic Lymphadenectomy and Cancer-Specific Survival in Patients with Lymph Node–Negative Urothelial Carcinoma of the Bladder Undergoing Radical Cystectomy. Annals of Surgical Oncology, 2011, 18, 2018-2025.	0.7	112
7	CXC Chemokine Receptor 4 is Essential for Maintenance of Renal cell Carcinoma-Initiating Cells and Predicts Metastasis. Stem Cells, 2013, 31, 1467-1476.	1.4	106
8	Complications of the AdVance Transobturator Male Sling in the Treatment of Male Stress Urinary Incontinence. Urology, 2010, 75, 1494-1498.	0.5	100
9	Lysis of Prostate Carcinoma Cells by Trifunctional Bispecific Antibodies (αEpCAM × αCD3). Journal of Histochemistry and Cytochemistry, 2001, 49, 911-917.	1.3	91
10	Results of the AdVance Transobturator Male Sling After Radical Prostatectomy and Adjuvant Radiotherapy. Urology, 2011, 77, 474-479.	0.5	90
11	Prospective Assessment of Malnutrition in Urologic Patients. Urology, 2009, 73, 1072-1076.	0.5	81
12	Lymph Node Density Affects Cancer-Specific Survival in Patients with Lymph Node–Positive Urothelial Bladder Cancer Following Radical Cystectomy. European Urology, 2011, 59, 712-718.	0.9	76
13	Long-term Outcomes of Salvage Lymph Node Dissection for Nodal Recurrence of Prostate Cancer After Radical Prostatectomy: Not as Good as Previously Thought. European Urology, 2020, 78, 661-669.	0.9	74
14	Dominance of CD4 <sup>+</sup> lymphocytic infiltrates with disturbed effector cell characteristics in the tumor microenvironment of prostate carcinoma. Prostate, 2008, 68, 1-10.	1.2	71
15	External Validation of Postoperative Nomograms for Prediction of All-Cause Mortality, Cancer-Specific Mortality, and Recurrence in Patients With Urothelial Carcinoma of the Bladder. European Urology, 2012, 61, 58-64.	0.9	69
16	BAP1 Immunohistochemistry Predicts Outcomes in a Multi-Institutional Cohort with Clear Cell Renal Cell Carcinoma. Journal of Urology, 2014, 191, 603-610.	0.2	69
17	Analysis of Sex Differences in Cancer-Specific Survival and Perioperative Mortality Following Radical Cystectomy: Results of a Large German Multicenter Study of Nearly 2500 Patients with Urothelial Carcinoma of the Bladder. Gender Medicine, 2012, 9, 481-489.	1.4	65
18	Staging of muscle-invasive bladder cancer: can computerized tomography help us to decide on local treatment?. World Journal of Urology, 2012, 30, 827-831.	1.2	63

#	Article	IF	Citations
19	Lymphovascular invasion is an independent predictor of oncological outcomes in patients with lymph nodeâ€negative urothelial bladder cancer treated by radical cystectomy: a multicentre validation trial. BJU International, 2010, 106, 493-499.	1.3	61
20	Optical coherence tomography for bladder cancer - ready as a surrogate for optical biopsy? - results of a prospective mono-centre study. European Journal of Medical Research, 2010, 15, 131.	0.9	60
21	Papillary vs clear cell renal cell carcinoma. Differentiation and grading by iodine concentration using DECTâ€"correlation with microvascular density. European Radiology, 2020, 30, 1-10.	2.3	57
22	Clinical and pathologic predictors of Gleason sum upgrading in patients after radical prostatectomy: Results from a single institution series. Urologic Oncology: Seminars and Original Investigations, 2011, 29, 508-514.	0.8	55
23	Gender-specific differences in cancer-specific survival after radical cystectomy for patients with urothelial carcinoma of the urinary bladder in pathologic tumor stage T4a. Urologic Oncology: Seminars and Original Investigations, 2013, 31, 1141-1147.	0.8	55
24	Outcome after PSMA PET/CT based radiotherapy in patients with biochemical persistence or recurrence after radical prostatectomy. Radiation Oncology, 2018, 13, 37.	1.2	54
25	Telehealth in Uro-oncology Beyond the Pandemic: Toll or Lifesaver?. European Urology Focus, 2020, 6, 1097-1103.	1.6	52
26	Contrast-enhanced transrectal ultrasound (CE-TRUS) with cadence-contrast pulse sequence (CPS) technology for the identification of prostate cancer. Urologic Oncology: Seminars and Original Investigations, 2011, 29, 295-301.	0.8	50
27	Risk factors for pelvic lymphoceles postâ€radical prostatectomy. International Journal of Urology, 2011, 18, 638-643.	0.5	50
28	Mesenchymal stem cells and glioma cells form a structural as well as a functional syncytium in vitro. Experimental Neurology, 2012, 234, 208-219.	2.0	49
29	Perioperative and oncologic outcomes of robot-assisted vs. open radical cystectomy in bladder cancer patients: A comparison of two high-volume referral centers. European Journal of Surgical Oncology, 2016, 42, 1736-1743.	0.5	49
30	Impact of preoperative hemoglobin and CRP levels on cancer-specific survival in patients undergoing radical cystectomy for transitional cell carcinoma of the bladder: results of a single-center study. World Journal of Urology, 2016, 34, 703-708.	1.2	48
31	Induction of Immune Mediators in Glioma and Prostate Cancer Cells by Non-Lethal Photodynamic Therapy. PLoS ONE, 2011, 6, e21834.	1.1	45
32	Risk factors for artificial urinary sphincter failure. World Journal of Urology, 2016, 34, 595-602.	1.2	45
33	Expression and Prognostic Significance of a Comprehensive Epithelial-Mesenchymal Transition Gene Set in Renal Cell Carcinoma. Journal of Urology, 2014, 191, 479-486.	0.2	44
34	Impact of <sup>68</sup> Ga-PSMA PET/CT on the Radiotherapeutic Approach to Prostate Cancer in Comparison to CT: A Retrospective Analysis. Journal of Nuclear Medicine, 2019, 60, 963-970.	2.8	44
35	CEACAM1: A Novel Urinary Marker for Bladder Cancer Detection. European Urology, 2010, 57, 648-654.	0.9	43
36	TOP2A, HELLS, ATAD2, and TET3 Are Novel Prognostic Markers in Renal Cell Carcinoma. Urology, 2017, 102, 265.e1-265.e7.	0.5	42

#	Article	IF	CITATIONS
37	Salvage lymph node dissection after 68Ga-PSMA or 18F-FEC PET/CT for nodal recurrence in prostate cancer patients. Oncotarget, 2017, 8, 84180-84192.	0.8	41
38	Human Renal Cell Carcinoma Induces a Dendritic Cell Subset That Uses T-Cell Crosstalk for Tumor-Permissive Milieu Alterations. American Journal of Pathology, 2011, 179, 436-451.	1.9	39
39	Shear-wave elastography of the testis in the healthy man – determination of standard values. Clinical Hemorheology and Microcirculation, 2016, 62, 273-281.	0.9	38
40	Clustering and Optimal Arrangement of Enzymes in Reaction-Diffusion Systems. Physical Review Letters, 2013, 110, 208104.	2.9	37
41	Radiotherapy of oligometastatic prostate cancer: a systematic review. Radiation Oncology, 2021, 16, 50.	1.2	37
42	"Finding the needle in a haystack― oncologic evaluation of patients treated for LUTS with holmium laser enucleation of the prostate (HoLEP) versus transurethral resection of the prostate (TURP). World Journal of Urology, 2017, 35, 1777-1782.	1.2	35
43	GDNF-Transduced Schwann Cell Grafts Enhance Regeneration of Erectile Nerves. European Urology, 2008, 54, 1179-1187.	0.9	34
44	Detection level and pattern of positive lesions using PSMA PET/CT for staging prior to radiation therapy. Radiation Oncology, 2017, 12, 176.	1.2	34
45	Differential Radioactive Proteomic Analysis of Microdissected Renal Cell Carcinoma Tissue by 54 cm Isoelectric Focusing in Serial Immobilized pH Gradient Gels. Journal of Proteome Research, 2005, 4, 2117-2125.	1.8	33
46	Interobserver Variability Limits Exact Preoperative Staging by Computed Tomography in Bladder Cancer. Urology, 2012, 79, 1317-1321.	0.5	33
47	Dramatic impact of blood transfusion on cancer-specific survival after radical cystectomy irrespective of tumor stage. Scandinavian Journal of Urology, 2017, 51, 130-136.	0.6	33
48	Malnutrition and clinical outcome in urological patients. European Journal of Medical Research, 2011, 16, 469.	0.9	32
49	Prognostic features for quality of life after radical cystectomy and orthotopic neobladder. International Braz J Urol: Official Journal of the Brazilian Society of Urology, 2016, 42, 1109-1120.	0.7	32
50	Tissue Phenomics for prognostic biomarker discovery in low- and intermediate-risk prostate cancer. Scientific Reports, 2018, 8, 4470.	1.6	32
51	Underestimation of Positron Emission Tomography/Computerized Tomography in Assessing Tumor Burden in Prostate Cancer Nodal Recurrence: Head-to-Head Comparison of <sup>68</sup> Ga-PSMA and <sup>11</sup> C-Choline in a Large, Multi-Institutional Series of Extended Salvage Lymph Node Dissections, Journal of Urology, 2020, 204, 296-302.	0.2	32
52	Downregulation of HNF-1B in Renal Cell Carcinoma Is Associated With Tumor Progression and Poor Prognosis. Urology, 2010, 76, 507.e6-507.e11.	0.5	31
53	Cell-based vaccines for renal cell carcinoma: genetically-engineered tumor cells and monocyte-derived dendritic cells. World Journal of Urology, 2005, 23, 166-174.	1.2	30
54	Radical cystectomy in the elderly patient: a contemporary comparison of perioperative complications in a single institution series. World Journal of Urology, 2010, 28, 445-450.	1.2	29

#	Article	IF	Citations
55	Patient-Reported Side Effects of Intradetrusor Botulinum Toxin Type A for Idiopathic Overactive Bladder Syndrome. Urologia Internationalis, 2011, 86, 68-72.	0.6	29
56	Risk stratification for locoregional recurrence after radical cystectomy for urothelial carcinoma of the bladder. World Journal of Urology, 2015, 33, 1753-1761.	1.2	28
57	The effect of BMI on clinicopathologic and functional outcomes after open radical prostatectomy. Urologic Oncology: Seminars and Original Investigations, 2014, 32, 297-302.	0.8	25
58	Long-Term Follow-Up and Oncological Outcome of Patients Undergoing Radical Cystectomy for Bladder Cancer following an Enhanced Recovery after Surgery (ERAS) Protocol: Results of a Large Randomized, Prospective, Single-Center Study. Urologia Internationalis, 2020, 104, 55-61.	0.6	25
59	Efficacy and safety of the ZSI375 artificial urinary sphincter for male stress urinary incontinence: lessons learned. World Journal of Urology, 2016, 34, 1457-1463.	1.2	23
60	Validation of mammalian target of rapamycin biomarker panel in patients with clear cell renal cell carcinoma. Cancer, 2015, 121, 43-50.	2.0	22
61	Preoperative mp-MRI of the prostate provides little information about staging of prostate carcinoma in daily clinical practice. World Journal of Urology, 2015, 33, 923-928.	1.2	22
62	Prognostic Features for Objectively Defined Urinary Continence after Radical Cystectomy and Ileal Orthotopic Neobladder in a Contemporary Cohort. Journal of Urology, 2017, 197, 210-215.	0.2	22
63	Validation of a High-End Virtual Reality Simulator for Training Transurethral Resection of Bladder Tumors. Journal of Surgical Education, 2019, 76, 568-577.	1.2	22
64	Therapeutic Vaccination with an Interleukin-2–Interferon-γ-Secreting Allogeneic Tumor Vaccine in Patients with Progressive Castration-Resistant Prostate Cancer: A Phase I/II Trial. Human Gene Therapy, 2009, 20, 1641-1651.	1.4	21
65	Optimization of collective enzyme activity via spatial localization. Journal of Chemical Physics, 2013, 139, 135101.	1.2	21
66	Effect of Hospital and Surgeon Case Volume on Perioperative Quality of Care and Short-term Outcomes After Radical Cystectomy for Muscle-invasive Bladder Cancer: Results From a European Tertiary Care Center Cohort. Clinical Genitourinary Cancer, 2017, 15, e809-e817.	0.9	21
67	Surgical High-risk Patients With ASAÂ≥ 3 Undergoing Radical Cystectomy: Morbidity, Mortality, and Predictors for Major Complications in a High-volume Tertiary Center. Clinical Genitourinary Cancer, 2018, 16, e1141-e1149.	0.9	21
68	Pathological upstaging detected in radical cystectomy procedures is associated with a significantly worse tumour-specific survival rate for patients with clinical T1 urothelial carcinoma of the urinary bladder. Scandinavian Journal of Urology and Nephrology, 2011, 45, 251-257.	1.4	20
69	Prediction of outcome in patients with urothelial carcinoma of the bladder following radical cystectomy using artificial neural networks. European Journal of Surgical Oncology, 2013, 39, 372-379.	0.5	20
70	Prospective evaluation of health-related quality of life after radical cystectomy: focus on peri- and postoperative complications. World Journal of Urology, 2017, 35, 1223-1231.	1.2	20
71	Health-related quality of life after radical cystectomy and ileal orthotopic neobladder: effect of detailed continence outcomes. World Journal of Urology, 2019, 37, 2385-2392.	1.2	20
72	Midterm Health-related Quality of Life After Radical Cystectomy: A Propensity Score–matched Analysis. European Urology Focus, 2020, 6, 704-710.	1.6	20

#	Article	IF	CITATIONS
73	Phase 1 Trial of Allogeneic Gene-Modified Tumor Cell Vaccine RCC-26/CD80/IL-2 in Patients with Metastatic Renal Cell Carcinoma. Human Gene Therapy, 2010, 21, 285-297.	1.4	19
74	Outcome Assessment of Patients With Metastatic Renal Cell Carcinoma Under Systemic Therapy Using Artificial Neural Networks. Clinical Genitourinary Cancer, 2012, 10, 37-42.	0.9	18
75	Schwann cellâ€mediated delivery of glial cell lineâ€derived neurotrophic factor restores erectile function after cavernous nerve injury. International Journal of Urology, 2013, 20, 344-348.	0.5	18
76	Perioperative patient education improves long-term satisfaction rates of low-risk prostate cancer patients after radical prostatectomy. World Journal of Urology, 2017, 35, 1205-1212.	1.2	18
77	An unrandomized prospective comparison of urinary continence, bowel symptoms and the need for further procedures in patients with and with no adjuvant radiation after radical prostatectomy. BJU International, 2003, 92, 360-364.	1.3	17
78	Postoperative upgrading of prostate cancer in men ≥75Âyears: a propensity score-matched analysis. World Journal of Urology, 2017, 35, 1517-1524.	1.2	17
79	Long-term Outcome of the Retrourethral Transobturator Male Sling After Transurethral Resection of the Prostate. International Neurourology Journal, 2016, 20, 335-341.	0.5	17
80	Multicenter evaluation of the prognostic value of pTO stage after radical cystectomy due to urothelial carcinoma of the bladder. BJU International, 2011, 108, E278-E283.	1.3	16
81	Open Complete Intrafascial Nerve-sparing Retropubic Radical Prostatectomy: Technique and Initial Experience. Urology, 2012, 79, 717-721.	0.5	16
82	High Immune Response Rates and Decreased Frequencies of Regulatory T Cells in Metastatic Renal Cell Carcinoma Patients after Tumor Cell Vaccination. Molecular Medicine, 2012, 18, 1499-1508.	1.9	16
83	Risk and timing of biochemical recurrence in pT3aN0/Nx prostate cancer with positive surgical margin $\hat{a} \in \mathbb{R}^m$ A multicenter study. Radiotherapy and Oncology, 2015, 116, 119-124.	0.3	16
84	The natural course of pT2 prostate cancer with positive surgical margin: predicting biochemical recurrence. World Journal of Urology, 2015, 33, 973-979.	1.2	16
85	Surgical learning curve for open radical prostatectomy: Is there an end to the learning curve?. World Journal of Urology, 2015, 33, 1721-1727.	1.2	16
86	Prognostic Value of the Preoperative Platelet-to-leukocyte Ratio for Oncologic Outcomes in Patients Undergoing Radical Cystectomy for Bladder Cancer. Clinical Genitourinary Cancer, 2017, 15, e915-e921.	0.9	16
87	Epidemiology and Treatment Barriers of Patients With Erectile Dysfunction Using an Online Prescription Platform: A Cross-Sectional Study. Sexual Medicine, 2020, 8, 370-377.	0.9	16
88	Assessing the Best Surgical Template at Salvage Pelvic Lymph Node Dissection for Nodal Recurrence of Prostate Cancer After Radical Prostatectomy: When Can Bilateral Dissection be Omitted? Results from a Multi-institutional Series. European Urology, 2020, 78, 779-782.	0.9	16
89	Individual Learning Curve Reduces the Clinical Value of Urinary Cytology. Clinical Genitourinary Cancer, 2011, 9, 22-26.	0.9	15
90	Virtual Reality Systems in Urologic Surgery: An Evaluation of the GreenLight Simulator. European Urology, 2013, 64, 687-688.	0.9	15

#	Article	IF	CITATIONS
91	Expression profiling of metastatic renal cell carcinoma using gene set enrichment analysis. International Journal of Urology, 2014, 21, 46-51.	0.5	15
92	Longâ€term functional outcome analysis in a large cohort of patients after radical prostatectomy. Neurourology and Urodynamics, 2018, 37, 2263-2270.	0.8	15
93	Risks and benefits of pelvic lymphadenectomy in octogenarians undergoing radical cystectomy due to urothelial carcinoma of the bladder. International Urology and Nephrology, 2017, 49, 2137-2142.	0.6	14
94	Disseminated Tumor Cells in Bone Marrow of Patients with Transitional Cell Carcinoma: Immunocytochemical Detection and Correlation with Established Prognostic Indicators. Journal of Urology, 2003, 169, 1303-1307.	0.2	13
95	Long-term Follow-up of Bladder Cancer Patients with Disseminated Tumour Cells in Bone Marrow. European Urology, 2011, 60, 231-238.	0.9	13
96	Do we need the nerve sparing radical prostatectomy techniques (intrafascial vs. interfascial) in men with erectile dysfunction? Results of a single-centre study. World Journal of Urology, 2015, 33, 301-307.	1.2	13
97	MRI-TRUS fusion biopsy of the prostate: Quality of image fusion in a clinical setting. Clinical Hemorheology and Microcirculation, 2019, 70, 433-440.	0.9	13
98	Integrative clinical transcriptome analysis reveals <i>TMPRSS2â€ERG</i> dependency of prognostic biomarkers in prostate adenocarcinoma. International Journal of Cancer, 2020, 146, 2036-2046.	2.3	13
99	Detection and Prognostic Value of Cytokeratin Positive Tumor Cells in Bone Marrow of Patients With Renal Cell Carcinoma. Journal of Urology, 2003, 170, 1747-1751.	0.2	12
100	Detection of urinary leakage after radical retropubic prostatectomy by contrast enhanced ultrasound – do we still need conventional retrograde cystography?. BJU International, 2010, 106, 1632-1637.	1.3	12
101	Preoperative Thrombocytosis in Patients Undergoing Radical Cystectomy for Urothelial Cancer of the Bladder: An Independent Prognostic Parameter for an Impaired Oncological Outcome. Urologia Internationalis, 2020, 104, 36-41.	0.6	12
102	Bladder Cancer Stage Development, 2004-2014 in Europe Compared With the United States: Analysis of European Population-based Cancer Registries, the United States SEER Database, and a Large Tertiary Institutional Cohort. Clinical Genitourinary Cancer, 2020, 18, 162-170.e4.	0.9	12
103	Impact of Routine Laboratory Parameters in Patients Undergoing Radical Cystectomy for Urothelial Carcinoma of the Bladder: A Long-Term Follow-Up. Urologia Internationalis, 2020, 104, 551-558.	0.6	12
104	Patients' Perspective on Digital Technologies in Advanced Genitourinary Cancers. Clinical Genitourinary Cancer, 2021, 19, 76-82.e6.	0.9	12
105	External validation of disease-free survival at 2 or 3 years as a surrogate and new primary endpoint for patients undergoing radical cystectomy for urothelial carcinoma of the bladder. European Journal of Surgical Oncology, 2012, 38, 637-642.	0.5	11
106	Prospective comparison of one year follow-up outcomes for the open complete intrafascial retropubic versus interfascial nerve-sparing radical prostatectomy. SpringerPlus, 2014, 3, 335.	1.2	11
107	Methadone enhances the effectiveness of 5â€aminolevulinic acidâ€based photodynamic therapy for squamous cell carcinoma and glioblastoma in vitro. Journal of Biophotonics, 2019, 12, e201800468.	1.1	11
108	Safety, efficacy and prognostic impact of immune checkpoint inhibitors in older patients with genitourinary cancers. Journal of Geriatric Oncology, 2020, 11, 1061-1066.	0.5	11

#	Article	IF	Citations
109	Frequency and prognostic relevance of disseminated tumor cells in bone marrow of patients with metastatic renal cell carcinoma. Cancer, 2006, 106, 1514-1520.	2.0	10
110	Prognostic value of pretreatment inflammatory markers in variant histologies of the bladder: is inflammation linked to survival after radical cystectomy?. World Journal of Urology, 2020, 39, 2537-2543.	1.2	10
111	Prognostic relevance of disseminated tumour cells in bone marrow of patients with transitional cell carcinoma. European Journal of Cancer, 2007, 43, 2678-2684.	1.3	9
112	Health-related quality of life after open and robot-assisted radical prostatectomy in low- and intermediate-risk prostate cancer patients: a propensity score-matched analysis. World Journal of Urology, 2020, 38, 3075-3083.	1.2	9
113	Digital Real-world Data Suggest Patient Preference for Tadalafil over Sildenafil in Patients with Erectile Dysfunction. European Urology Focus, 2022, 8, 794-802.	1.6	9
114	Health-Related Quality of Life following Cytoreductive Radical Prostatectomy in Patients with De-Novo Oligometastatic Prostate Cancer. Cancers, 2021, 13, 5636.	1.7	9
115	Expression of plakoglobin in renal cell carcinoma. Anticancer Research, 1998, 18, 4231-5.	0.5	9
116	Recovery of erectile function comparing autologous nerve grafts, unseeded conduits, Schwann cell seeded guidance tubes and GDNF-overexpressing Schwann cell grafts. DMM Disease Models and Mechanisms, 2016, 9, 1507-1511.	1.2	8
117	Is It Safe to Offer Radical Cystectomy to Patients above 85 Years of Age? A Long-Term Follow-Up in a Single-Center Institution. Urologia Internationalis, 2020, 104, 975-981.	0.6	8
118	Establishment and Validation of an Individualized Cell Cycle Process-Related Gene Signature to Predict Cancer-Specific Survival in Patients with Bladder Cancer. Cancers, 2020, 12, 1146.	1.7	8
119	Trade-offs and design principles in the spatial organization of catalytic particles. Nature Physics, 2022, 18, 203-211.	6.5	8
120	External Validation of a Risk Model to Predict Recurrence-Free Survival After Radical Cystectomy in Patients With Pathological Tumor Stage T3NO Urothelial Carcinoma of the Bladder. Journal of Urology, 2012, 187, 1210-1214.	0.2	7
121	The increase of stage, grading, and metastases in patients undergoing radical prostatectomy during the last decade. World Journal of Urology, 2019, 37, 1103-1109.	1.2	7
122	Outcome After 68Ga-PSMA-11 versus Choline PET-Based Salvage Radiotherapy in Patients with Biochemical Recurrence of Prostate Cancer: A Matched-Pair Analysis. Cancers, 2020, 12, 3395.	1.7	7
123	Initial Experience with Radical Prostatectomy Following Holmium Laser Enucleation of the Prostate. European Urology Focus, 2020, 7, 1247-1253.	1.6	7
124	PSMA-positive nodal recurrence in prostate cancer. Strahlentherapie Und Onkologie, 2020, 196, 637-646.	1.0	7
125	Mapping Telemedicine in German Private Practice Urological Care: Implications for Transitioning beyond the COVID-19 Pandemic. Urologia Internationalis, 2021, 105, 650-656.	0.6	7
126	Risk of biochemical recurrence and timing of radiotherapy in pT3aÂNO prostate cancer with positive surgical margin. Strahlentherapie Und Onkologie, 2016, 192, 440-448.	1.0	6

#	Article	IF	CITATIONS
127	Follow-up of high-risk bladder cancerâ€"Is it safe to perform fluorescence endoscopy multiple times in the same patient?. Urologic Oncology: Seminars and Original Investigations, 2017, 35, 602.e19-602.e23.	0.8	6
128	Baseline Health-related Quality of Life Predicts Bladder Cancer–specific Survival Following Radical Cystectomy. European Urology Focus, 2022, 8, 1659-1665.	1.6	6
129	Impact of previous mesh hernia repair on the performance of open radical prostatectomy - complications and functional outcome. BJU International, 2010, 106, 1628-1631.	1.3	5
130	Benefits and Complications during the Stay at an Early Rehabilitation Facility after Radical Cystectomy and Orthotopic Ileum Neobladder Reconstruction. Urologia Internationalis, 2019, 103, 350-356.	0.6	5
131	Detection of Gleason 6 prostate cancer in patients with clinically significant prostate cancer on multiparametric magnetic resonance imaging. Clinical Hemorheology and Microcirculation, 2019, 73, 105-111.	0.9	5
132	Prognostic impact of perioperative blood transfusions on oncological outcomes of patients with bladder cancer undergoing radical cystectomy: A systematic review. Arab Journal of Urology Arab Association of Urology, 2021, 19, 24-30.	0.7	5
133	Salvage cystectomy and ileal conduit urinary diversion as a lastâ€ine option for benign diseases—perioperative safety and postoperative healthâ€related quality of life. Neurourology and Urodynamics, 2021, 40, 1154-1164.	0.8	5
134	Long-term Health-related Quality of Life (HRQOL) After Radical Cystectomy and Urinary Diversion - A Propensity Score-matched Analysis. Clinical Genitourinary Cancer, 2022, 20, e283-e290.	0.9	5
135	Poor standard mp-MRI and routine biopsy fail to precisely predict intraprostatic tumor localization. World Journal of Urology, 2016, 34, 1383-1388.	1.2	4
136	Prospective evaluation of 4-D contrast-enhanced-ultrasound (CEUS) imaging in bladder tumors. Clinical Hemorheology and Microcirculation, 2020, 74, 1-12.	0.9	4
137	Does Pandemic Anxiety Affect Urology Health Care Workers?. Urologia Internationalis, 2021, 105, 192-198.	0.6	4
138	Definition and Impact on Oncologic Outcomes of Persistently Elevated Prostate-specific Antigen After Salvage Lymph Node Dissection for Node-only Recurrent Prostate Cancer After Radical Prostatectomy: Clinical Implications for Multimodal Therapy. European Urology Oncology, 2022, 5, 285-295.	2.6	4
139	PD-L1 expression in bladder cancer: Which scoring algorithm in what tissue?. Urologic Oncology: Seminars and Original Investigations, 2021, 39, 734.e1-734.e10.	0.8	4
140	Postoperative change in Gleason score of prostate cancer in fusion targeted biopsy: a matched pair analysis. Scandinavian Journal of Urology, 2021, 55, 27-32.	0.6	4
141	Partial Nephrectomy in pT3a Tumors Less Than 7 cm in Diameter Has a Superior Overall Survival Compared to Radical Nephrectomy. Cureus, 2019, 11, e5781.	0.2	4
142	Retrospective evaluation of the impact of non-oncologic chronic drug therapy on the survival in patients with bladder cancer. International Journal of Clinical Pharmacy, 2022, 44, 339-347.	1.0	4
143	Shikonin enhances the antitumor effect of cabazitaxel in prostate cancer stem cells and reverses cabazitaxel resistance by inhibiting ABCG2 and ALDH3A1. American Journal of Cancer Research, 2020, 10, 3784-3800.	1.4	4
144	Computed-tomography based scoring system predicts outcome for clinical lymph node-positive patients undergoing radical cystectomy. International Braz J Urol: Official Journal of the Brazilian Society of Urology, 2022, 48, 89-98.	0.7	4

#	Article	lF	CITATIONS
145	Accuracy and prognostic value of radiological lymph node features in variant histologies of bladder cancer. World Journal of Urology, 2022, 40, 1707-1714.	1.2	4
146	The molecular basis of prostate cancer cell escape from protoporphyrin IX-based photodynamic therapy. Medical Laser Application: International Journal for Laser Treatment and Research, 2009, 24, 237-246.	0.4	3
147	Co-occurrence features characterizing gland distribution patterns as new prognostic markers in prostate cancer whole-slide images. , $2016$ , , .		3
148	Impact of previous transurethral prostate surgery on health-related quality of life after radical prostatectomy: Does the interval between surgeries matter?. World Journal of Urology, 2021, 39, 1431-1438.	1.2	3
149	Predictive clinical features for negative histopathology of MRI/Ultrasound-fusion-guided prostate biopsy in patients with high likelihood of cancer at prostate MRI: Analysis from a urologic outpatient clinic1. Clinical Hemorheology and Microcirculation, 2021, 76, 503-511.	0.9	3
150	Diagnostic and Prognostic Role of miR-192 in Different Cancers: A Systematic Review and Meta-Analysis. BioMed Research International, 2021, 2021, 1-14.	0.9	3
151	Patient-Reported and Oncological Outcomes of Salvage Therapies for PSMA-Positive Nodal Recurrent Prostate Cancer: Real-Life Experiences and Implications for Future Trial Design. Frontiers in Oncology, 2021, 11, 708595.	1.3	3
152	RISK OF MALNUTRITION IN UROLOGICAL PATIENTS. Journal of Urology, 2009, 181, 8-8.	0.2	2
153	Urine colour after radical prostatectomy predicts urinary leakage at the vesicourethral anastomosis. Scandinavian Journal of Urology and Nephrology, 2012, 46, 337-342.	1.4	2
154	The impact of bladder neck mucosal eversion during open radical prostatectomy on bladder neck stricture and urinary extravasation. International Urology and Nephrology, 2012, 44, 1403-1410.	0.6	2
155	MOP-dependent enhancement of methadone on the effectiveness of ALA-PDT for A172 cells by upregulating phosphorylated JNK and BCL2. Photodiagnosis and Photodynamic Therapy, 2020, 30, 101657.	1.3	2
156	A matter of size? Healthâ€related quality of life after radical prostatectomy for patients with giant prostates. Prostate, 2021, 81, 443-451.	1.2	2
157	Age at surgery is not a prognostic factor for the AdVanceâ€XP male sling efficacy: A postâ€hoc analysis of a prospective 7â€year multicentric study. Neurourology and Urodynamics, 2021, 40, 1616-1624.	0.8	2
158	Choosing a Specialist: An Explanatory Study of Factors Influencing Patients in Choosing a Urologist. Urologia Internationalis, 2021, 105, 749-756.	0.6	2
159	Prognostic Value of Pretreatment Inflammatory Markers in Patients Receiving Radical Cystectomy for Urothelial Bladder Cancer: Does Age Matter?. Urologia Internationalis, 2022, 106, 832-839.	0.6	2
160	Occurrence of symptomatic lymphocele after open and robot-assisted radical prostatectomy. Central European Journal of Urology, 2021, 74, 341-347.	0.2	2
161	Can we define reliable risk factors for anastomotic strictures following radical prostatectomy?. Urologia, 2020, 87, 170-174.	0.3	1
162	Image-Guided Robotic Radiosurgery for the Treatment of Lung Metastases of Renal Cell Carcinoma—A Retrospective, Single Center Analysis. Cancers, 2022, 14, 356.	1.7	1

#	Article	IF	CITATIONS
163	Health-related quality of life as a prognostic indicator of biochemical recurrence free survival in high-risk prostate cancer patients following radical prostatectomy Journal of Clinical Oncology, 2022, 40, 235-235.	0.8	1
164	Age and ECOG Performance Status as Predictors of Survival of Patients with Upper Urinary Tract Urothelial Carcinoma Undergoing Radical Nephroureterectomy. Urologia Internationalis, 2023, 107, 72-79.	0.6	1
165	Reply by Authors. Journal of Urology, 2020, 204, 302-302.	0.2	0
166	Combined Open Prostatectomy and Kidney Surgery: Feasibility and 12-Month Outcome. Research and Reports in Urology, 2021, Volume 13, 815-821.	0.6	0
167	Clinical Implication of Borderline CT-Morphological Metastatic Spread in Bladder Cancer: What You See Is Not Always What You Got. Urologia Internationalis, 2022, , 1-10.	0.6	0
168	The prognostic impact of preoperative health-related quality life on bladder cancer-specific survival in patients treated with radical cystectomy Journal of Clinical Oncology, 2022, 40, 475-475.	0.8	0
169	The Added Value of Baseline Health-Related Quality of Life in Predicting Survival in High-Risk Prostate Cancer Patients Following Radical Prostatectomy. Journal of Urology, 0, , .	0.2	0